Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03306641 · ClinicalTrials.gov registry record · NA
A One-Week Crossover Dispensing Evaluation of New Daily Wear Soft Contact Lenses
A NA study of Myopia, sponsored by CooperVision.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT03306641: Completed NA study of Myopia, sponsored by CooperVision.
NCT03306641 is a NA study of Myopia that has completed, run by CooperVision. The registered enrollment target is 45 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03306641, a NA study of Myopia, has completed, sponsored by CooperVision.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to validate the clinical performance of a new contact lens design when worn over a period 1 week compared to nelfilcon A (control).
Primary Outcome
Overall lens fit acceptance was measured on a scale of 0-4 in 0.25 steps (0=can't be worn, 1=Poor, 2=Fair, 3=Good, 4=Optimum)
Conditions Studied
Interventions
- DEVICE Test Contact Lens
- DEVICE Nelfilcon A
Study Locations (1)
Indiana
- Clinical Optics Research Lab (CORL) Indiana University School of Optometry, Indiana University - Bloomington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-07-28 |
| Est. Completion | 2017-08-31 |
| Phase | NA |
What the finished NCT03306641 record still lists
NCT03306641 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Test Contact Lens is the first listed.
NCT03306641 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT03306641 about?
NCT03306641 is a clinical study titled "A One-Week Crossover Dispensing Evaluation of New Daily Wear Soft Contact Lenses". The purpose of this study is to validate the clinical performance of a new contact lens design when worn over a period 1 week compared to nelfilcon A (control).
What is the current status of trial NCT03306641?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2017-07-28. Estimated completion is 2017-08-31.
What conditions does trial NCT03306641 study?
This clinical trial studies the following conditions: Myopia.
What interventions are being tested in trial NCT03306641?
The interventions under investigation include: Test Contact Lens (DEVICE), Nelfilcon A (DEVICE).
Who is sponsoring clinical trial NCT03306641?
This trial is sponsored by CooperVision, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03306641 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03306641's enrollment target sits among peer trials
45 77th of 90 higher than 14 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI